Clinical Trials · NCT00565097

Lanreotide as Treatment of Polycystic Livers

CompletedPhase 2/Phase 3Lanreotide (Approved)
Phase
Phase 2/Phase 3
Recruitment status
Completed
Sponsor
Radboud University Medical Center
Enrollment
38
Start date
Oct 2007
Locations
2 sites, Belgium, Netherlands
Primary endpoint
Reduction of total liver volume as determined by CT scan
View Lanreotide compound reference